LinkedIn
WebsiteIntroduction
Cabaletta Bio Inc (NASDAQ: CABA) is a clinical-stage biotechnology company founded in 2017 and headquartered in Philadelphia, Pennsylvania. Its proprietary CABA® platform applies Chimeric Antigen Receptor T cell (CAR T) technology to target B cells in patients with autoimmune diseases. The company's name refers to a "cabaletta," a section of an operatic aria characterized by rapid, technically demanding passages—an analogy for Cabaletta Bio's objective of advancing product development across various indications.
| Metric | Value |
|---|---|
| Price (2025-10-09) | $3.1398 |
| Daily Change | +30.28% |
| Volume | 7,405,945 |
| Exchange | NASDAQ |
| Ticker | CABA |
Corporate Structure and Leadership
Cabaletta Bio employs approximately 100 staff, covering research, clinical operations, manufacturing, and corporate functions. Senior management includes:
- Steven Nichtberger, M.D. – Co-founder, President, Chief Executive Officer, and Chairman. Dr. Nichtberger previously led Tengion, served as an adjunct professor at the Wharton School, and held roles at Merck.
- Jon Basu, M.D. – Chief Scientific Officer since December 2019. Dr. Basu oversees discovery, preclinical, and translational research; he joined from Adaptimmune Therapeutics.
- Marisa Binder, Ph.D. – President of Science & Technology. Dr. Binder established Cabaletta’s translational and manufacturing operations after roles at Adaptimmune and the University of Pennsylvania.
Biotechnology by Sangharsh Lohakare
Clinical Pipeline and Research Platform
Cabaletta Bio’s pipeline focuses on engineered T cell therapies for autoimmune diseases:
- CABA-201 (RESETR™ Phase 1/2) – A fully human CD19-CAR T cell candidate in clinical trials for systemic lupus erythematosus (SLE), myositis, systemic sclerosis (SSc), and generalized myasthenia gravis (MG).
- MuSK-CAART – A Phase 1 candidate for MuSK-antibody positive MG.
- Regulatory designations – Received FDA Fast Track designations for dermatomyositis, SLE, lupus nephritis, SSc, and multiple sclerosis; also received Regenerative Medicine Advanced Therapy (RMAT) designation in myositis.
Recent Developments
- On August 7, 2025, Cabaletta Bio released its second quarter 2025 financial results, detailing continued investment in clinical programs and expansion to 40 active U.S. trial sites.
- On September 3, 2025, Dr. Nichtberger participated in a fireside chat at the Cantor Global Healthcare Conference to discuss plans for engaging European regulators in 2026.
- At the European Society of Gene and Cell Therapy Annual Congress on September 10–13, 2025, the company presented data indicating that a single infusion of CABA-201 without preconditioning achieved complete B cell depletion and clinical responses in pemphigus vulgaris patients.
- On October 1, 2025, Cabaletta reported no grade 3–4 cytokine release syndrome in 5 of 8 evaluable patients across RESET SLE, Myositis, and SSc cohorts; three mild cases were resolved with standard care.
Financial and Strategic Analysis
CABA shares increased by 30.28% on October 9, 2025, following a Zacks Rank upgrade to #2 (Buy), attributed to upward revisions to earnings estimates. Institutional interest is based on anticipated registrational trial designs and potential European expansion in 2026. The company’s cash position, enhanced by a financing round in July 2025, is expected to fund planned Phase 2/3 studies into 2027.
Market Position and Industry Context
Cabaletta Bio operates in the emerging field of cell therapy targeting autoimmunity. Competitors include Autolus, Poseida Therapeutics, and academic programs focused on developing CAR T or chimeric autoantibody receptor T (CAART) therapies. Cabaletta’s emphasis on durable treatments for indications that typically require long-term immunosuppression differentiates its platform in a market predominantly focused on oncology.
tl;dr
- CABA shares rose 30.28% to $3.14 on October 9, 2025, after a Zacks Rank upgrade to #2.
- August 7 Q2 2025 results detailed funding position and 40 active U.S. trial sites for CABA-201.
- September 2025 data at ESGCT indicated CAR T monotherapy achieving full B cell depletion in pemphigus vulgaris without preconditioning.
- Plans include engaging with European regulators in 2026 and initiating registrational trials, with financial resources to support Phase 2/3 programs through 2027.
